Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 0.56 |
| ▸ | PSEN2 | P49810 | 20/20 | 0.56 |
| ▸ | APH1B | Q8WW43 | 20/20 | 0.56 |
| ▸ | NCSTN | Q92542 | 20/20 | 0.56 |
| ▸ | APH1A | Q96BI3 | 20/20 | 0.56 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249739 | 0.83 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3412213 | 0.82 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3408115 | 0.81 | PSEN1 (0.65) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3406491 | 0.81 | PSEN1 (0.63) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3406685 | 0.81 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2258104 | 0.79 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14036533 | 0.78 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4103642 | 0.78 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3795011 | 0.78 | PSEN1 (0.64) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7855567 | 0.77 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | PSEN1 6/4885PSEN2 8/4885APH1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.